INPP5D and neoplasm: LILRB4 recruited SHP2 and SHIP1 to activate ERK1/2 pathway, thereby promoting EMT and upregulating VEGF-A expression, which in turn enhances tumor cell migration, invasion, and angiogenesis (Figure 4B) 230.